Tyra Biosciences, Inc. (TYRA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $33.78: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 50.50; Below-average business quality.
Tyra Biosciences is a clinical-stage oncology company developing oral FGFR inhibitors using its proprietary SNÅP platform, with lead program oral dabogratinib in Phase 2 trials for LG-UTUC (SURF303), IR NMIBC (SURF302), and achondroplasia (BEACH301). Two additional clinical... Read more
Sell if holding. Engine safety override at $33.78: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 50.50; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.5/10, moderate confidence.
Passes 9/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.33, news boost analyst cluster(6), earnings proximity 85d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — Tyra Biosciences, Inc.
Latest news
- This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday — benzinga May 19, 2026 neutral
- This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday — benzinga May 19, 2026 positive
- This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday — benzinga May 19, 2026 neutral
- Wolfe Research Initiates Coverage On Tyra Biosciences with Peer Perform Rating — benzinga May 19, 2026 neutral
- HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $45 Price Target — benzinga May 14, 2026 positive
Generated 2026-05-20T20:21:22Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $33.78: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 50.50; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $31.42. Score 5.5/10, moderate confidence.
Take-profit target: $44.50 (+31.7% upside). Prior stop was $31.42. Stop-loss: $31.42.
Quality below floor (1.2 < 4.0).
Tyra Biosciences, Inc. trades at a P/E of N/A (forward -11.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover TYRA with a consensus score of 4.4/5. Average price target: $51.
What does Tyra Biosciences, Inc. do?Tyra Biosciences is a clinical-stage oncology company developing oral FGFR inhibitors using its proprietary SNÅP...
Tyra Biosciences is a clinical-stage oncology company developing oral FGFR inhibitors using its proprietary SNÅP platform, with lead program oral dabogratinib in Phase 2 trials for LG-UTUC (SURF303), IR NMIBC (SURF302), and achondroplasia (BEACH301). Two additional clinical programs, TYRA-430 (FGFR4, Phase 1 for HCC) and TYRA-200 (FGFR1/2/3, Phase 1 for resistant ICC), round out the pipeline.